

**Friday February 16th**

<i>Opening Remarks</i>	8:45	Nichols, Charles	President, ISRP
<i>Session 1</i>	<b>Preclinical Rodent Models I</b>		
	9:00	Murnane, Kevin	Preclinical and clinical studies of psychedelics for methamphetamine addiction
	9:15	Jaster, Alaina	Psilocybin alters behavior and cellular mechanisms associated with rewarding effects of opioids
	9:30	Damaj, M. Imad	Effect of Classical Psychedelics on Chronic Neuropathic Pain in Mice
	9:45	Peters, Jamie	Preclinical models identify 5-HT2A receptors as a therapeutic target for opioid use disorder with comorbid alcohol use
	10:00	Woodburn, Samuel	Acute psilocybin effects during fear extinction drive persisting behavioral changes
<i>Break</i>	10:15	15 minutes	
<i>Session 2</i>	<b>Clinical I</b>		
	10:30	Doss, Manoj	The Impact of Psychedelics on Episodic Memory Encoding and Retrieval
	10:45	Rosen, David	Naturalistic Psychedelics-Use is Associated with Altered Social Decision-Making: Increases in Compassion and Decreases in Nationalism
	11:00	Sepeda, Nathan	Personality changes after psilocybin use: A pooled mega-analysis of clinical trial data
	11:15	Goldy, Sean	Comparing first-time psychedelic and cannabis experiences: Insights into challenging and positive subjective effects
	11:30	Winston, Brian	Psilocybin Shifts Brain Response Patterns to Music Systematically Across Subjects
<i>Lunch Break</i>	11:45	until 1pm	
<i>session 3</i>	<b>Chemistry</b>		
	1:00	Cunningham, Mike	Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs
	1:15	Wallach, Jason	A Medicinal Chemistry Approach to Functionally Selective 5-HT2A Receptor Drug Discovery
	1:30	Carrera, Ignacio	Semisynthetic ibogaine analogs as inhibitors of the human serotonin transporter
	1:45	Sherwood, Alex	Psychedelic-like activity of norpsilocin analogs
	2:00	Hernandez, Gonzolo	Psychedelics from a natural products and analytical chemistry point of view
	2:15	Younkin, Jason	Pharmacological characterization of quipazine analogs as a new structural class of psychedelic 5-HT2A receptor agonists
	2:30	de la Fuente Revenga, Mario	Levels of canonical 5-HT2A activation in the mouse cortex differentiate psychedelics from homeostatic levels of serotonin – insights from a novel technology.
<i>Break</i>	2:45	15 minutes	
<i>Session 4</i>	<b>Clinical II</b>		
	3:00	Gukasayan, Natalie	Preliminary findings on treatment response from a large survey of individuals with HPPD
	3:15	Ching, Terence	Safety, tolerability, and clinical effects of single-dose psilocybin with non-directive support in the treatment of obsessive-compulsive disorder: Results from a randomized, double-blind, placebo-controlled trial
	3:30	Schindler, Emmanuelle	From Busting to Bench: Patient-informed regimen of psilocybin in the treatment of cluster headache
	3:45	Weiss, Brandon	Ayahuasca in the Treatment of Post-traumatic Stress Disorder: Mixed Methods Case Series Evaluation in Military Combat Veterans
	4:00	Walsh, Zach	Microdose.me: Findings from the first stage of a large, naturalistic, citizen-science study.
	4:15	Lucas, Philippe	The Global Psychedelic Survey; Primary Outcomes of a Large International Survey of Adult Psychedelic Consumers
	4:30	Garcia-Romeu, Al	Pilot study of Psilocybin for Post-treatment Lyme Disease

*Opening Reception 5:30-7:00pm*

**Saturday February 17th**

Breakfast provided 7:30 till 9:00 At the hotel

Session 6 **Regulatory and grants**  
9:00 Bonson, Kit Assessing the Abuse Potential of Psychedelics  
- (FDA)  
9:30 Grant, Steve Grant writing for psychedelic research projects  
- (Former NIDA program officer)  
10:00 TBD

Break 10:15 15 minutes

Session 7 **Anti-inflammatory effects of Psychedelics**  
10:45 Foster, Tim The Role of Serotonin and the 5-HT2A Receptor in Ocular Disease: A Through the Looking Glass View of the Therapeutic Potential of Psychedelics in Inflammation- and Aging- Associated Disease Processes  
11:00 Galbato, Thomas The Role of the Serotonin 2A Receptor in the Progression of Age-Related Macular Degeneration  
11:15 Nichols, Charles Psychedelics as a treatment for Rheumatoid Arthritis  
11:30 Flanagan, Thomas Functional Selectivity of 5-HT2A Receptor Activation in Pulmonary Tissues in an Ovalbumin-Induced Murine Allergic Asthma Model

Business meeting (full members only) Lunch provided 12pm-1:15pm

Session 8  
1:15 Barret, Fred Preliminary effects of psilocybin in patients with major depressive disorder and co-occurring alcohol use disorder  
1:30 Marek, Gerard Pharmacokinetic, subjective and pharmacodynamic effects of the novel 5-HT2A receptor agonist GM-2505 in healthy volunteers showing robust psychedelic effects expected of a potent 5-HT2A receptor agonist: Promise for future studies in patients with MDD  
1:45 Sayali, Ceyda The costs and benefits of psychedelics on cognition and mood  
2:00 Gannon, Brenda Interceptive Effects of LSD and 5 LSD Analogues in Male Sprague Dawley Rats  
2:15 Luoma, Jason MDMA-AT for Social Anxiety Disorder: Treatment Adaptation and Mechanisms of Action  
2:30 Fantegrossi, Bill Pro-social effects of MDMA and novel entactogens in the autism-like BTBR mouse

Break 3:00 15 minutes

Session 9 **Receptor/Pharmacology**  
3:15 Rasenick, Mark A simple protein biomarker reveals continuity of antidepressant properties, at the cellular level, for monoaminergic antidepressants, ketamine and psychedelics.  
3:30 Gonzales-Maeso, Javier Translation-independent association of mRNAs encoding protomers of the psychedelic 5-HT2A-mGlu2 receptor complex in living cells  
3:45 McCorvy, John Profiling psychedelics across the serotonin GPCRome reveals strategies for receptor selectivity and biased agonism  
4:00 Cunningham, Kathryn Targeted Synthetic Entities as Selective 5-HT2A Receptor Modulators  
4:15 Pottie, Eline Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of  $\beta$ -arrestin 2 and miniGqq bioassays  
4:30 Glatfelter, Grant Pharmacological profiles and psychedelic-like effects of 4-hydroxy-, 4-acetoxy-, and 4-methoxy-N-methyl-N-isopropyltryptamine  
4:45 Baumann, Michael In vivo evidence for conversion of 4-acetoxy-N,N-dimethyltryptamine (psilacetin) to its bioactive metabolite 4-hydroxy-N,N-dimethyltryptamine (psilocin) in male rats

Poster Session and reception 5-6:30pm

**Sunday February 18th**

Session 10	<b>Substance Use Disorders</b>		
	8:45	Johnson, Matt	Clinical trial comparing psilocybin to nicotine patch for tobacco addiction
	9:00	Naude, Gideon	Behavioral Economic Demand Predicts Successful Psilocybin-Assisted Cigarette Smoking Abstinence at 6-Months
	9:15	Grossman, Daniel	Examining US National Trends in Psychedelic Use and Mental Illness
	9:30	Rich, Rhianna	Visual Healing, a nature-themed video intervention, may increase nature relatedness but not social connectedness in psilocybin-assisted therapy for alcohol use disorder.
	9:45	Banks, Matthew	Co-administration of midazolam and psilocybin: Differential effects on subjective quality versus memory of the psychedelic experience
	10:00	Buzzi, Belle	Psilocybin reduces drug withdrawal in both 5-HT2A and non-5-HT2A-dependent mechanisms in mice
<i>Break</i>	<i>10:15</i>	<i>15 minutes</i>	
Session 11	<b>Preclinical Rodent Models II</b>		
	10:30	Wenthur, Cody	Transient Elevation of Plasma Glucocorticoids Supports Psilocybin-Induced Anxiolysis in Mice
	10:45	Tiwari, Praachi	Unveiling Cross-Species Psychedelic Potential through Neural Circuits of Anxiety, OCD and Learned Helplessness.
	11:00	Zahid, Zarveen	Increased plasticity and metaplasticity in murine hippocampus but not prefrontal cortex following psychedelic administration
	11:15	Kwan, Alex	Cell-type specificity in the neural plasticity evoked by psilocybin
	11:30	Dwiel, Lucas	A proof-of-concept for psychedelic-assisted brain stimulation
<i>Closing remarks</i>	11:45	ISRP	
<i>End of meeting</i>	12:00		

## **POSTERS**

Noelle	Anastasio	Biosignature of genetic knockdown of the 5-HT2A receptor in rat medial prefrontal cortex: Implications for uncovering psychedelic mechanisms
Matthew	Baggott	Stereoisomers of 5-(2-methylaminobutyl)benzofuran (5-MABB) have differential effects on monoamine transporters and physiological parameters in rats
Austen	Casey	Toward a mechanistic understanding of MDMA's dual role in sociability and fear memory
Mike	Cunningham	Novel Class of Psychedelic Ibogaine Analogs Demonstrate Efficacy in Preclinical Models of Opioid Use Disorder Without Cardiotoxicity
Andrew	Gaddis	Psilocybin for Opioid Use Disorder: Design Considerations for Two Parallel Randomized Double-Blind Trials Investigating Psilocybin with Buprenorphine
Jasper	Heinsbroek	Tabernanthalog reduces motivation for heroin and alcohol in a polydrug use model
Thomas	Kelly	Psilocybin analog 4-OH-DiPT enhances fear extinction and GABAergic inhibition of principal neurons in the basolateral amygdala
Adam	Klein	Preclinical profile of GM-1020, a novel, orally bioavailable NMDA antagonist
Sandeep	Nayak	Classic psychedelics and drug interactions
Tashia	Petker	Psilocybin-assisted psychotherapy for opioid tapering in chronic pain
Eline	Pottie	Identification of psychedelic new psychoactive substances (NPS) showing biased agonism at the 5-HT2AR through simultaneous use of $\beta$ -arrestin 2 and miniGaq bioassays
Jeremie	Richard	Psychedelics in the Treatment of Gambling Disorder and Other Behavioral Addictions: A Scoping Review
Grace	Schwartz	Sex and depressive symptoms were associated with reductions in heavy drinking days with psilocybin-assisted therapy for alcohol use disorder
Jeremy	Scott	Attitudes & Perceptions of Psilocybin Among Clinical Trial Personnel
Richa	Tyagi	Psychedelic Tryptamines for Auditory Hypersensitivity in Fragile X Syndrome: A Preclinical Study using Fmr1 Knockout Mice
M. Frances	Vest	Examining the Impact of Naturalistic Psychedelic Use on Executive Function and Negative Affect in Individuals Recently Abstinent from Methamphetamine
Hannah	Whitmore	Psychedelic-Assisted Therapy for Death Acceptance in Terminally Ill Patients
Bo Jarrett	Wood	Psilocybin and Synthetic Psychedelic 2,5-methoxy-4-iodoamphetamine (DOI) Attenuate the Rewarding and Reinforcing Effects of Methamphetamine
Mary "Bit"	Yaden	Psychedelic Medicine in Psychiatry Education
David	Yaden	The Hopkins-Oxford Psychedelic Ethics (HOPE) Consensus Statement
Jason	Younkin	Pharmacological characterization of quipazine analogs as a new structural class of psychedelic 5-HT2A receptor agonists
Brittany	Youssef	Mystical experience scores increased from first to second psilocybin dosing session in participants with alcohol use disorder: clinical implications of repeated psilocybin sessions
Zarmeen	Zahid	Study Protocol for RECAP 2.0: Role of Experience versus reCALL and Plasticity in psilocybin's long-term behavioral effects
Rick	Zirkel	Two-photon in vivo imaging of psychedelic actions on cerebral blood flow and neurovascular coupling